HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Use of tenofovir disoproxil fumarate in highly viremic, hepatitis B mono-infected pregnant women.

AbstractBACKGROUND:
Antiviral therapy in addition to immunoprophylaxis at birth has been shown to further reduce perinatal transmission of hepatitis B virus (HBV) in highly viremic women.
AIMS:
The aim of this study was to describe the use of tenofovir disoproxil fumarate (TDF) prophylaxis to reduce maternal HBV DNA levels and potentially vertical transmission in highly viremic women.
METHODS:
After receiving IRB approval, we performed a retrospective chart review of mothers positive for hepatitis B surface antigen (HBsAg) who delivered between 2009 and 2012. We identified women with HBV DNA levels ≥6 log copies/mL who were treated with TDF in pregnancy.
RESULTS:
There were 22 women identified. The majority were of Micronesian ethnicity. All were negative for hepatitis C antibody and HIV infection. The median gestational age of TDF initiation was 31 weeks with a median duration of treatment of 45 days. There was a reduction in median HBV DNA levels from baseline 9.0 ± 2.0 to 5.4 ± 1.1 log copies/mL after treatment. There were five (22.7 %) preterm deliveries and five (22.7 %) cesarean deliveries. All infants received immunoprophylaxis at birth. Postnatal HBsAg testing at 9-12 months was available for 13 infants, 12 of which were negative. There was one case of perinatal transmission.
CONCLUSIONS:
This is the second published case series to date on the use of TDF prophylaxis in HBV mono-infected, highly viremic mothers. This series suggests the use of TDF in pregnancy reduces maternal HBV DNA levels and is well tolerated.
AuthorsPai-Jong Stacy Tsai, Ann Chang, Seiji Yamada, Naoky Tsai, Marguerite Lisa Bartholomew
JournalDigestive diseases and sciences (Dig Dis Sci) Vol. 59 Issue 11 Pg. 2797-803 (Nov 2014) ISSN: 1573-2568 [Electronic] United States
PMID24898100 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiviral Agents
  • DNA, Viral
  • Organophosphonates
  • Tenofovir
  • Adenine
Topics
  • Adenine (administration & dosage, analogs & derivatives, therapeutic use)
  • Adolescent
  • Adult
  • Antiviral Agents (administration & dosage, therapeutic use)
  • DNA, Viral (blood)
  • Female
  • Hepatitis B (drug therapy)
  • Humans
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical (prevention & control)
  • Odds Ratio
  • Organophosphonates (administration & dosage, therapeutic use)
  • Pregnancy
  • Risk Factors
  • Tenofovir
  • Viremia
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: